January 14, 2020

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

EGFR-TKI treatment was associated with changes in the TME of EGFR-mutated NSCLC, and such changes may provide clues for optimization of subsequent PD-1 inhibitor treatment.

Bookmark

Cite This Study

Isomoto et al. (Tue,) studied this question.

synapsesocial.com/papers/69dcca0fc099bcfdbb133a7b https://doi.org/https://doi.org/10.1158/1078-0432.ccr-19-2027

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes2011 · 169 citations
2Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.2016 · 180 citations
3Increased CD73 and reduced IFNG signature expression in relation to response rates to anti-PD-1(L1) therapies in EGFR-mutant NSCLC.2017 · 45 citations
4Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers2017 · 578 citations
5Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 20122014 · 29,046 citations